ClinicalTrials.gg
Not yet recruitingNCT05647096NUC-CAPUpdated Nov 29, 2024

Safety, Tolerability and Performance of the NucleoCapture Device in the Reduction of Circulating CfDNA/NETs in Subjects with Sepsis

An interventional study of NucleoCapture device in Sepsis and Respiratory Failure, sponsored by Santersus AG. Not yet recruiting at 9 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-11-29.

Sponsored by Santersus AG · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
73
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 95 studies in Sepsis with a site in United Kingdom — 14 open to participants now, 14 under way, 1 of them phase 3. Sepsis · United Kingdom.

Planned enrollment
34th of 45
73 · median 215
Started
2025
with 3 others
No phase
12 of 95
1 open now
Primary completion
2027-05
later than 9 of 13 live
Registered
80th of 95
by date

Among the 95 studies in Sepsis with a site in United Kingdom, this one is the 34th largest by planned enrollment of the 45 interventional ones that give a count, is one of 4 that started in 2025, is one of 12 with no phase, reaches primary completion later than 9 of the 13 other live ones, and was the 80th registered.

Sepsis

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

14 of the 95 studies in Sepsis with a site in United Kingdom are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies in Sepsis with a site in United Kingdom, or all of them as a file.
02

Study summary

This is a prospective, multinational, multicentre, randomised, parallel-group, open-label study to assess the safety, tolerability and performance of the NucleoCapture extracorporeal apheresis device in the reduction of circulating cell-free DNA (cfDNA)/Neutrophil Extracellular Traps (NETs) in sepsis patients.

Read the detailed description

This study investigates the safety, tolerability and performance of the NucleoCapture extracorporeal apheresis device in patients with sepsis and respiratory failure. Sepsis is a common condition in hospital settings and is associated with high rates of morbidity and mortality and despite ongoing development in the treatment and supportive care of sepsis, mortality remains considerable.

cfDNA/NET therapeutic apheresis with NucleoCapture is indicated for the treatment of sepsis and for the treatment/prevention of septic shock. Participants will be randomised to receive either standard of care (SOC) or SOC plus NucleoCapture treatment, SOC will be according to the current guidelines described by the Surviving Sepsis Campaign: international guidelines for the management of sepsis and septic shock. Participants in the SOC plus NucleoCapture arm will receive one treatment session with NucleoCapture per day, for the first three days. Each treatment session with NucleoCapture will last for up 6 hours, aiming to treat 4.5 plasma volumes. Treatment sessions with NucleoCapture treating less than 3.5 plasma volumes will be counted as incomplete and the treatment session will be repeated on the following day, up to day 5 maximum.

Assessments and tests will take place for all participants whilst in Intensive Care Unit (ICU) on days 1 to 5, day 7, day 14, day 21 and day 28. Participants transferred to ward-based care before day 28 will receive no further study assessment visits from the point of transfer to ward-based care, apart from day 28 in which participants will receive a final study assessment visit.

03

Conditions studied

  • Sepsis
  • Respiratory Failure

Keywords

  • Sepsis
  • Respiratory failure
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients aged 18-75
  • Proven or suspected respiratory sepsis aetiology
  • Acute respiratory failure currently requiring invasive mechanical ventilation for not more than 48 hours duration
  • Horowitz Index for Lung Function (Pa02/Fi02 Ratio) ≤200mmHg or ≤26.6kPa
  • Sequential organ failure assessment score (SOFA) ≥4 and ≤ 14
  • Have provided written or consent is given by the patient's legally designated representative or an independent physician (if possible, according to local law).

Exclusion criteria

Exclusion Criteria:

  • Expected duration of invasive mechanical ventilation less than 48 hours
  • The use of other non-routine extracorporeal sepsis treatments such as very high flux renal replacement therapy (>60ml/kg/h total exchange), use of high cut off filters or other non-routine extracorporeal treatment columns such as Cytosorb, Toramyxcin, etc).
  • Presence of severe multiple organ failure at the point of enrolment as evidenced by:

    • Severe vasoplegic failure

      • Norepinephrine dose > 0.60 μg/kg/min
      • Use of epinephrine
    • Concomitant cardiogenic shock, clinically suspected or CI\<2.2 if measured

      • Use of dobutamine, epinephrine, phosphodiesterase inhibitors or levosimendan
    • Coagulopathy as defined by count \<50
  • Calculated Plasma Volume greater than 5000ml as determined by an estimation of total blood volume (according to Nadler's formula, incorporating height, weight and sex) multiplied by (1- Haematocrit). A total blood volume calculator is available at https://www.omnicalculator.com/health/blood-volume
  • Long term oxygen therapy or home oxygen use
  • Liver cirrhosis ( proven or clinically suspected)
  • Active bleeding
  • Citrate intolerance if citrate is required for therapeutic apheresis
  • Heparin allergy if heparin is required for therapeutic apheresis
  • disease with of \<12 months and score of at least 2
  • Haematological if not in remission
  • Solid organ transplant and concomitant use of
  • Dialysis dependent Chronic Kidney Disease (CKD Stage 5-D)
  • Prior use of cardiopulmonary resuscitation (CPR) in index admission
  • Requirement for extracorporeal membrane oxygenation (ECMO)
  • Patient expected to die within 48 hours of admission to ICU
  • Known allergy to components of NucleoCapture
  • Current Participation in another interventional clinical trial
  • Pregnancy (as established by the presence of beta human chorionic gonadotropin in urine or blood)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
73 participants (estimated)

Study arms

  • Experimental
    NucleoCapture Treatment

    Participants in the NucleoCapture treatment arm will receive Standard of Care plus three treatment sessions with the NucleoCapture treatment device. The device consists of 100ml NucleoCapture selective adsorber.

    Device: NucleoCapture device

  • No intervention
    Standard of Care

    Participants in the Standard of Care arm will receive standard medical care alone.

Interventions

  • DeviceNucleoCapture device

    100ml NucleoCapture selective DNA adsorber

06

What researchers measure

Primary outcomes

  1. To demonstrate the NucleoCapture column reduces the amount of cfDNA/NETs in the plasma of participants with sepsis and respiratory failure

    The mean reduction of an expected ≥50% of the net amount of cfDNA/NETs across the NucleoCapture column at the end of each NuceoCapture treatment session

    Time frame: Within 6 hours from the baseline (pre-column) plasma

Secondary outcomes

  1. Mean reduction in circulating cfDNA/NETs measured by circulating blood levels of nucleosomes (H.3.1)

    Mean relative reduction of circulating blood cfDNA/NETs at the end of a complete treatment session with NucleoCapture compared to the change in the mean levels of cfDNA/NETs over a 6 hour period in the SOC treatment arm

    Time frame: Before and after treatment with the NucleoCapture column and at the start and end of a 6 hour period in the SOC treatment arm

  2. The clinical benefit of the NucleoCapture column in participants with sepsis and respiratory failure

    Change in organ support and survival

    Time frame: From date of randomisation to day 21 for organ support and day 28 for survival

Other outcomes

  1. The biological efficacy and performance of NucleoCapture will be assessed using routine biomarkers

    Routine organ function, haematology, coagulation and inflammation biomarkers will be measured

    Time frame: At baseline, days 1 to 5, day 7 and day 14

  2. The biological efficacy and performance of NucleoCapture will be assessed using non-routine biomarkers

    Non-routine biomarkers of inflammation and coagulation will be measured

    Time frame: At baseline, days 1 to 5, day 7 and day 14

  3. Device handling and usability

    Usability and handling of the device will be assessed in the intervention arm

    Time frame: Day 1 up to day 5

07

Study locations

9 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2025; primary completion for May 2027, 22 months later.

Of 326 interventional studies with no phase under Sepsis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 39. This study's planned 22 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2022
First posted
Dec 12, 2022
StartEst.
Jul 1, 2025
Primary completionEst.
May 5, 2027
CompletionEst.
May 28, 2027
Last update
Nov 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05647096
Lead sponsor
Santersus AG
Collaborators
ISS AG
Responsible party
Sponsor
First posted
Dec 12, 2022
Start date
Jul 1, 2025 (estimated)
Primary completion
May 5, 2027 (estimated)
Completion
May 28, 2027 (estimated)
Last update
Nov 29, 2024

Study contacts

Emma Barsoum
Contact
eb@santersus.com
+447806820434
Andrew Aswani
principal investigator · Santersus AG

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion